Search Results - Gordon Cook

Refine Results
  1. 1

    HOW TO TREAT UNFIT AND FRAIL PATIENTS by Gordon Cook

    Published in HemaSphere (2022-04-01)
    Get full text
    Article


  2. 2

    Artificial intelligence methods applied to longitudinal data from electronic health records for prediction of cancer: a scoping review by Victoria Moglia, Owen Johnson, Gordon Cook, Marc de Kamps, Lesley Smith

    Published in BMC Medical Research Methodology (2025-01-01)
    Get full text
    Article


  3. 3

    A comparison of peripheral blood stem cell collection outcomes for multiple myeloma; mobilization matters in the era of IMiD induction by Thea Chandler, Christopher Parrish, Marina Karakantza, Jonathan Carmichael, David Pawson, Gordon Cook, Frances Seymour

    Published in eJHaem (2023-08-01)
    Get full text
    Article


  4. 4

    Benefits of switching from intravenous to subcutaneous daratumumab: Perspectives from UK healthcare providers by Gordon Cook, John Ashcroft, John Ashcroft, Mariana Fernandez, Sarah Henshaw, Zeyad Khalaf, Guy Pratt, Anish Tailor, Neil Rabin

    Published in Frontiers in Oncology (2023-02-01)
    Get full text
    Article


  5. 5

    High loading dose AmBisome® is efficacious and well tolerated in the management of invasive fungal infection in hematology patients by Lorna A. McLintock, Gordon Cook, Tessa L. Holyoake, Brian L. Jones, Sally E. Kinsey, Graham H. Jackson

    Published in Haematologica (2007-04-01)
    Get full text
    Article


  6. 6

    What can we do about patients presenting with myeloma and severe renal failure? Observations from the UK MERIT plasma exchange trial by Judith Behrens, Gill Gaskin, Neil Iggo, Jonathan Barratt, Jane Tighe, Richard Soutar, Gordon Cook, Mary Drake, Curly Morris, Mark Drayson

    Published in eJHaem (2023-02-01)
    Get full text
    Article


  7. 7

    Doubling in median survival in patients diagnosed with multiple myeloma 2005-2019; a real-world study from the UK’s Haematological Malignancy Research Network by Alexandra Smith, Timothy Bagguley, Eve Roman, Simon Crouch, Russell Patmore, Ruth De Tute, Andy Rawstron, Gordon Cook, Frances Seymour, Christopher Parrish

    Published in Haematologica (2025-03-01)
    Get full text
    Article


  8. 8

    Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. by Sylvia Feyler, Gina B Scott, Christopher Parrish, Sarah Jarmin, Paul Evans, Mike Short, Katherine McKinley, Peter J Selby, Gordon Cook

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  9. 9

    The UK consensus supporting effective introduction of novel treatments for multiple myeloma in the National Health Service by Rakesh Popat, Supratik Basu, Sarah Henshaw, Kamaraj Karunanithi, Karthik Ramasamy, Inderjit Singh, Anish Tailor, Ian Walker, Tim Warren, Noreen Ali, Charles Duffield, Gordon Cook

    Published in eJHaem (2024-12-01)
    Get full text
    Article


  10. 10

    Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort by Eve Roman, Alexandra Smith, Russell Patmore, Debra Howell, Gordon Cook, Robert Newton, Eleanor Kane, Ruth de Tute, Maxine JE Lamb, Daniel Painter, Timothy Bagguley, Andrew Rawstron

    Published in BMJ Open (2021-02-01)
    Get full text
    Article


  11. 11

    Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic by Jonathan Carmichael, Frances Seymour, Graham McIlroy, Sarrah Tayabali, Rosie Amerikanou, Sylvia Feyler, Rakesh Popat, Guy Pratt, Christopher Parrish, A. John Ashcroft, Graham H. Jackson, Gordon Cook

    Published in Blood Cancer Journal (2023-03-01)
    Get full text
    Article


  12. 12

    Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results by Holger W. Auner, Sarah R. Brown, Katrina Walker, Jessica Kendall, Bryony Dawkins, David Meads, Gareth J. Morgan, Martin F. Kaiser, Mark Cook, Sadie Roberts, Christopher Parrish, Gordon Cook

    Published in Blood Cancer Journal (2022-04-01)
    Get full text
    Article


  13. 13

    Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial by Charlotte Pawlyn, David Cairns, Tom Menzies, John Jones, Matthew Jenner, Gordon Cook, Kevin Boyd, Mark Drayson, Martin Kaiser, Roger Owen, Walter Gregory, Gareth Morgan, Graham Jackson, Faith Davies

    Published in Haematologica (2020-12-01)
    Get full text
    Article


  14. 14

    Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data by Martin Kortüm, Sebastian Theurich, James Farrell, Graham Jackson, Gordon Cook, Joseph C. Cappelleri, Olivia Ashman, Shanti Neff-Baro, Aline Gauthier, Khalil Jewiti-Rigondza, Alaeddine Sidhom, Ashraf Chaudhary, Christof Scheid

    Published in BMC Cancer (2025-08-01)
    Get full text
    Article


  15. 15

    The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients wi... by Alina Striha, A. John Ashcroft, Anna Hockaday, David A. Cairns, Karen Boardman, Gwen Jacques, Cathy Williams, John A. Snowden, Mamta Garg, Jamie Cavenagh, Kwee Yong, Mark T. Drayson, Roger Owen, Mark Cook, Gordon Cook

    Published in Trials (2018-03-01)
    Get full text
    Article


  16. 16

    The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review by Hira Mian, Arleigh McCurdy, Smith Giri, Shakira Grant, Bram Rochwerg, Erica Winks, Ashley E. Rosko, Monika Engelhardt, Charlotte Pawlyn, Gordon Cook, Graham Jackson, Sara Bringhen, Thierry Facon, Alessandra Larocca, Sonja Zweegman, Tanya M. Wildes

    Published in Blood Cancer Journal (2023-01-01)
    Get full text
    Article


  17. 17

    Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen by Ruth M. de Tute, Andy C. Rawstron, Walter M. Gregory, J. Anthony Child, Faith E. Davies, Sue E. Bell, Gordon Cook, Alexander J. Szubert, Mark T. Drayson, Graham H. Jackson, Gareth J. Morgan, Roger G. Owen

    Published in Haematologica (2016-02-01)
    Get full text
    Article


  18. 18

    Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation... by Esa Jantunen, Carmen Canals, Alessandro Rambaldi, Gert Ossenkoppele, Bernardino Allione, Didier Blaise, Eulogio Conde, Hervè Tilly, Gordon Cook, Fiona Clark, Andrea Gallamini, Andrew Haynes, Nicolas Mounier, Peter Dreger, Michael Pfreundschuh, Anna Sureda, for the EBMT Lymphoma Working Party

    Published in Haematologica (2008-12-01)
    Get full text
    Article


  19. 19

    Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network by Philippe Moreau, Pieter Sonneveld, Mario Boccadoro, Gordon Cook, Ma Victoria Mateos, Hareth Nahi, Hartmut Goldschmidt, Meletios A. Dimopoulos, Paulo Lucio, Joan Bladé, Michel Delforge, Roman Hajek, Heinz Ludwig, Thierry Facon, Jesus F. San Miguel, Hermann Einsele

    Published in Haematologica (2019-12-01)
    Get full text
    Article


  20. 20

    Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry by Adam Irving, Dennis Petrie, Anthony Harris, Laura Fanning, Erica M. Wood, Elizabeth Moore, Cameron Wellard, Neil Waters, Kim Huynh, Bradley Augustson, Gordon Cook, Francesca Gay, Georgia McCaughan, Peter Mollee, Andrew Spencer, Zoe K. McQuilten

    Published in PLoS ONE (2024-01-01)
    Get full text
    Article


Search Tools: